LENZ Therapeutics, Inc. Common Stock

LENZNASDAQ • USD
ThemeBiotech - Drug Development›Clinical-Stage Platforms
4.13 USD
↗ 0.04 (0.98%)AT CLOSE (03:59 PM EST)
4.17
↗ 0.04 (1.04%)
POST MARKET (AS OF 04:14 PM EST)
Post Market
AS OF 04:14 PM EST
4.17
↗ 0.04 (1.04%)
🔴Market: CLOSED

Shares of LENZ Therapeutics, Inc. Common Stock (LENZ) are trading at $4.13. There is a divergence between signals — technical indicators rate "Buy" but underlying fundamentals lean "Sell". Notable factors include a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 0/9, negative Return on Equity and a bearish Death Cross on the long-term moving averages. Valuation metrics place LENZ at a fair price relative to peers.

Technical & fundamental data as of Nov 13, 2026.

Open?$4.06
High?$4.17
Low?$3.91
Prev. Close?$4.09
Volume?748.6K
Avg. Volume?1.1M
VWAP?$4.07
Rel. Volume?0.70x
Bid / Ask
Bid?$4.12 × 100
Ask?$4.23 × 700
Spread?$0.11
Midpoint?$4.18
Valuation & Ratios
Market Cap?129.8M
Shares Out?31.4M
Float?19.5M
Float %?62.0%
P/E Ratio?N/A
P/B Ratio?0.68
EPS?-$4.46
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing therapies to improve vision and developing ophthalmic pharmaceutical products. Its products VIZZ (aceclidine ophthalmic solution) 1.44% is a once-daily eye drop developed to restore clear near vision for up to 10 hours. VIZZ is powered by aceclidine, highlighted by its differentiated mechanism of action as a predominantly pupil-selective miotic that interacts with the iris, with minimal ciliary muscle stimulation.
Themes
Biotech - Drug Development›Clinical-Stage PlatformsLongevity & Aging›Age-Related Therapeutics
Employees
152
Market Cap
128.5M
Industry
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Website
www.lenz-tx.com
Listed
2024-03-22
Address
201 LOMAS SANTA FE DRIVE, SUITE 300
SOLANA BEACH, CA 92075
Phone: 858-925-7000
Technical OutlookBuy
Strong SellNeutralStrong Buy
Long-Term (Tide)?▲ Bullish(+1/3)
Medium-Term (Wave)?▲ Bullish(+2/3)
Short-Term (Ripple)?▲ Bullish(+1/3)
MA Alignment?Mixed
Full Technical Analysis →
Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?
3
Z-Score?
10
Momentum?
35
Short Sent.?
33
Piotroski F-Score?0/9Weak
Altman Z-Score?0.96Distress
Confidence?64%Moderate
Full Fundamental Analysis →
Short InterestSqueeze Risk
Short % of Float?36.28%Squeeze Risk
Short Interest?7.1M
Days to Cover?5.6
Free Float19.5M
Avg Daily Volume1.3M
Settlement Date2026-10-30
Financial Health
Current Ratio?11.66Strong
Quick Ratio?11.39Strong
Cash Ratio?1.72Strong
Debt/Equity?0.00Low
ValuationFAIRLY VALUEDvs 1 peers + S&P 500
Score
67/100
P/E?
N/A▾
P/B?
Peers
100
S&P
97
0.68CHEAP▾
P/S?
Peers
100
S&P
7
10.50HIGH▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-0.7CHEAP▾
EV/Sales?
Peers
100
S&P
17
8.03HIGH▾
Returns & Efficiency
ROE?
S&P
3
-73.0%WEAK▾
ROA?
S&P
3
-66.9%WEAK▾
Cash Flow & Enterprise
FCF?$-127703000
Enterprise Value?$99.2M
Fundamentals ratios updated end of day
MarketsMoversWatchlist